

Neurobiology of Dementias

Group leader

Fortea Ormaechea, Juan (FGS)

Researchers

Alcolea Rodríguez, Daniel Andrés (FGS)
 Arranz Martínez, Javier Jose (FGS)
 Arriola Infante, Jose Enrique (IR)
 Bejanin , Alexandre Pierre Armand (IR)
 Belvis Nieto, Robert (FGS)
 Carmona Iragui, Maria (FGS)
 Del Hoyo Soriano, Laura (IR)
 Dols Icardo, Oriol (IR)
 Gimenez Badia, Sandra (FGS)
 Illan Gala, Ignacio (FGS)
 Lleo Bisa, Alberto (FGS)
 Rodríguez Baz, Iñigo (IR)
 Rubio Guerra, Sara (FGS)
 Sánchez Aced, Erika (IR)
 Santos Santos, Miguel Angel (FGS)
 Sirisi Dolcet, Sónia (IR)
 Valle Tamayo, Natalia (IR)
 Videla Toro, Laura (IR)
 Zhu , Nuole (IR)

Research Technicians

Alvarez Sánchez, Esther (IR)
 Aumatell Escabias, Joaquim (IR)
 Canovas Segura, Ana Belen (IR)
 Carreras Vega, Mireia (IR)
 Clos Batet, Susana (IR)
 El Bachiri Azzahchi, Sumia (IR)
 El Bounasri El Bennadi, Shaimaa (IR)
 Farre Maduell, Ariadna (IR)
 Filella Merce, Julia (IR)
 García Hernandez, Estefania (IR)
 Gasull Vicens, Laia (IR)
 Gellida Castan, Èlia (IR)
 Lorente Gordillo, Oriol (IR)
 Marques Kiderle, Sónia Karin (IR)
 Maure Blesa, Lucia (IR)
 Morcillo Nieto, Alejandra Omaira (IR)
 Mota Rodríguez, Cecilia (IR)
 Muñoz Llahuna, Laia (IR)
 Palmieri Zinna, Marisa Alejandra (IR)
 Pegueroles Monllau, Jordi (IR)
 Reyes Santiago, Daniel (CIBER/IR)
 Ribas Bellavista, Laia (IR)
 Ribosa Nogue, Roser (IR)
 Rozalem Aranha, Mateus (IR)
 Sala Matavera, Isabel (FGS)
 Sánchez López, Oriol (CIBER/IR)
 Sánchez Saudinos, Maria Belen (IR)
 Sanjuan Hernandez, Aida (IR)
 Selma Gonzalez, Judit (IR)
 Subirana Castillo, Andrea (IR)
 Torres Alcalá, Soraya (IR)
 Valldenu Castells, Silvia (IR)
 Vaque Alcazar, Lidia (IR)
 Vera Campuzano, Elena (IR)
 Zsadanyi , Sara Erzsebet (IR)



DESCRIPTION

This multidisciplinary team is made up of more than 40 researchers including neurologists, neuropsychologists, biologists, biochemists, engineers and laboratory technicians. This is a highly translational team combining basic research with clinical research in humans to advance our understanding of these diseases. The group is very productive in generating publications and attracting competitive resources. The group regularly trains national and international residents, Master's students and pre- and postdoctoral researchers. The group offers an excellent place for the training of young researchers in a unique translational environment.

MAIN LINES OF RESEARCH

- Identification and characterization of novel biomarkers for the diagnostic and prognostic evaluation of patients with neurodegenerative diseases.
- Understanding the natural history of Alzheimer's disease clinical and biomarker changes in people with Down syndrome.
- Understanding the genetic causes underlying neurodegenerative disorders and developing new genetic-based biomarkers to aid in disease diagnosis and prognosis.
- Characterizing the molecular mechanisms underlying neurodegenerative dementias.
- Digital neuropathology applied to neurodegenerative diseases.
- The intersection between sleep, epilepsy, and Alzheimer's disease.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- Clinical trials in Alzheimer's disease and Down syndrome.

SCIENTIFIC CHALLENGES

Since its founding over 15 years ago, our group has experienced continual and exponential growth and is firmly consolidated as a leader in translational research into neurodegenerative dementias. We currently have a total of 11 principal investigators of active, competitive research grants. Although this is a positive sign of our growth in recent years, it also brings with it many organizational challenges that need to be met. Within our research setting, our group is a relative exception not only in size but also in the levels of clinical care and scientific excellence achieved. Moving forward, our objective is to maintain a sustainable growth without compromising on the values and vision that we have sustained until now and that have made this growth possible.

Recent advances in the field of Dementia are expected to herald a revolution in the coming years that will have a substantial impact on our clinical and research activity. For example, digital tools and plasma biomarkers are already here and pharmacological treatments that change the course of Alzheimer's disease could be available in the next 24 months. The detection of low abundant proteins in plasma requires ultrasensitivity, such as that provided by Single Molecule Array (SIMOA) digital ELISA technology (Quanterix), which is available in our group. Combined with our active participation in multiple clinical trials, our group is perfectly placed to lead the charge in this field and adapt to these changes.

Based on the aforementioned advances, the challenges moving forward include:

- Maintain our scientific production and funding, prioritizing the projects with higher impact.
- Consolidate our number of granted projects in European and international applications.
- Unfold the potential to collaborate with pharma and technological companies to foster additional patent applications and contracts.
- Adapt our research in response to the integration of the first disease-modifying therapy.
- Continue to innovate by developing ever more sensitive technologies for digital and blood based biomarkers.

ACTIVE GRANTS

- Alcolea Rodríguez, Daniel Andrés. Utilidad diagnóstica de A β 42 y A β 42/40 en LCR y plasma para detectar amiloidosis cerebral y correlación con marcadores subrogados de producción de β -amiloide en enf. de Alzheimer. PI18/00435. Instituto de Salud Carlos III (ISCIII). Duration: 2019-2023. 147.620,00 €.
- Alcolea Rodríguez, Daniel Andrés. Caracterización multimodal de las etapas prodrómicas del espectro Alzheimer-Lewy. PI22/00611. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2025. 153.670,00 €.
- Alcolea Rodríguez, Daniel Andrés. Technology validation of full automated plasma assay based on the chemiluminescence immunoassay technique for the 4 biomarkers, b-amyloid 42/40, t-Tau, p-Tau181 and Neurofilament light in Alzheimer's disease. PNC00126. SYS-ALZ-2022-01. Non competitive. Sysmex Inostics GMBH. Duration: 2022-2023. 51.750,00 €.
- Arranz Martinez, Javier Jose. Contractes Rio Hortega 2021. CM21/00243. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2023. 65.000,00 €.
- Arriola Infante, Jose Enrique. Contratos Rio Hortega 2022. CM22/00219. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2024. 65.000,00 €.
- Bejanin, Alexandre Pierre Armand. Contractes Miguel Servet I 2020. CP20/00038. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2026. 202.500,00 €.
- Bejanin, Alexandre Pierre Armand. Neuroimagen multimodal de la enfermedad de pequeños vasos relacionada con la enfermedad de Alzheimer en el síndrome de Down. PI22/00307. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2025. 165.770,00 €.
- Bejanin, Alexandre Pierre Armand. Multimodal imaging of small vessel disease in genetic AD. AARG-22-923680. Alzheimer's Association. Duration: 2022-2025. 126.532,76 €.
- Carmona Iragui, Maria. Estudio de biomarcadores bioquímicos y de imagen de angiopatía amiloide cerebral en el continuum de la enfermedad de Alzheimer esporádica y asociada al síndrome de Down. PI18/00335. Instituto de Salud Carlos III (ISCIII). Duration: 2019-2023. 68.970,00 €.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- Carmona Iragui, Maria. Caracterización de la epilepsia y de los trastornos de sueño en la enfermedad de Alzheimer esporádica y asociada al síndrome de Down. PI22/00785. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2025. 135.520,00 €.
- Carmona Iragui, Maria. Inflammatory biomarkers along the Alzheimer's disease continuum in down syndrome. JLF 2020 M CARMONA. Jérôme Lejeune Fondation. Duration: 2020-2023. 86.694,20 €.
- Carmona Iragui, Maria. Multimodal assessment of brain inflammatory biomarkers in DS-associated AD. AARG-22-973966. Alzheimer's Association. Duration: 2023-2025. 141.246,28 €.
- Dols Icardo, Oriol. Estudio longitudinal del papel de las células inmunitarias periféricas en la evolución de la ELA. FUND.HNA. Fundación HNA. Duration: 2021-2023. 100.000,00 €.
- Dols Icardo, Oriol. Estudio transcriptómico de la demencia frontotemporal para la comprensión de sus bases moleculares e identificación de biomarcadores que reflejen su sustrato neuropatológico in vivo. PI18/00326. Instituto de Salud Carlos III (ISCIII). Duration: 2019-2023. 135.520,00 €.
- Dols Icardo, Oriol. Caracterización transcriptómica y neuropatológica del tejido postmortem de pacientes con esclerosis lateral amiotrófica portadores de la expansión en el gen C9orf72. PI21/01395. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2024. 87.120,00 €.
- Dols Icardo, Oriol. Assessing peripheral inflammation in DS at different stages of AD. AARF-22-924456. Alzheimer's Association. Duration: 2022-2025. 147.402,61 €.
- Fortea Ormaechea, Juan. INMUNGEN-CoV2: Estudio genético de la severidad de COVID-19. F. TATIANA PREDOC 2020. Fundación Tatiana Pérez de Guzmán El Bueno. Duration: 2021-2024. 39.160,00 €.
- Fortea Ormaechea, Juan. Contractes per a la intensificació de l'activitat investigadora al SNS 2021. INT21/00073. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2023. 60.000,00 €.
- Fortea Ormaechea, Juan. Caracterización de la inflamación relacionada con amiloide: nuevos marcadores inflamatorios y su impacto en la macroestructural y microestructura cortical en la enfermedad de Alzheimer preclínica y prodrómica. PI20/01473. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2023. 214.775,00 €.
- Fortea Ormaechea, Juan. Mes-CoBraD: Multi-disciplinary Expert System for the Assessment & Management of Complex Brain Disorders. MES-CoBraD 965422. Unión Europea. Duration: 2021-2024. 482.771,25 €.
- Fortea Ormaechea, Juan. The Role of Inflammation and NGF Dysfunction in the Evolution of Alzheimer Disease Pathology in Down syndrome. NIH THE REGENTS 1R01AG056850-01A1. The Regents of the University of California. Duration: 2018-2023. 1.872.312,87 €.
- Fortea Ormaechea, Juan. Clinical trials to prevent Alzheimer's Disease in Down Syndrome. NIH SOUTHERN R33AG066543. University of Southern California. Duration: 2019-2024. 340.242,00 €.
- Fortea Ormaechea, Juan. Exosomal Tau Pathology in Down Syndrome. R01AG061566. National Institute of Aging (NIH-NIA). Duration: 2018-2023. \$ 10.000,00 €.
- Gimenez Badia, Sandra. Síndrome de apnea-hipopnea del sueño y síndrome de Down: cognición, biomarcadores de Enfermedad de Alzheimer en plasma, líquido cefalorraquídeo y resonancia magnética. PI20/00836. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2023. 77.440,00 €.
- Gimenez Badia, Sandra. The impact of Alzheimer's disease on sleep in adults with Down Syndrome. JLF #1801 -S GIMENEZ. Jérôme Lejeune Fondation. Duration: 2020-2024. 86.699,13 €.
- Gimenez Badia, Sandra. Evaluation of the circadian rest-activity rhythm in adults with DS. GBHI ALZ UK-23-971107. Alzheimer's Association. Duration: 2023-2026. 24.987,00 €.
- Illan Gala, Ignacio. Contractes Juan Rodés 2020. JR20/00018. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2024. 180.000,00 €.
- Illan Gala, Ignacio. Avanzando la clasificación de la demencia frontotemporal y la esclerosis lateral amiotrófica mediante neuroimagen microestructural y funcional, y biomarcadores sanguíneos de neurodegeneración y neuroinflamación.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- PI21/00791. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2024. 129.470,00 €.
- Illan Gala, Ignacio. Unveiling the impact of biological sex along sporadic and genetic FTL. AACSF-21-850193. Alzheimer's Association. Duration: 2021-2024. 147.286,04 €.
- Lleo Bisa, Alberto. Acúmulo de Proteína Precursora de Amiloide-C99 (APP-C99) como mecanismo de enfermedad en la enfermedad de Alzheimer: implicaciones terapéuticas. PI20/01330. Instituto de Salud Carlos III (ISCIII). Duration: 2021-2023. 183.920,00 €.
- Lleo Bisa, Alberto. NEUROBIOLOGIA DE LES DEMENCIAS. 2022 INV-1 00048. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Duration: 2022-2024. 66.217,84 €.
- Lleo Bisa, Alberto. Estudio de la patología sináptica de Tau mediante Array Tomography y microscopia de superresolución. FUND. TATIANA 2022. Fundación Tatiana Pérez de Guzmán El Bueno. Duration: 2023-2025. 33.000,00 €.
- Lleo Bisa, Alberto. iLEADS AlzAss. SG-23-1014431 iLEADS. Alzheimer's Association. Duration: 2022-2023. 59.831,52 €.
- Padilla Franco, Concepción. Contractes Sara Borrell 2020. CD20/00133. Instituto de Salud Carlos III (ISCIII). Duration: 2011-2022. 80.598,00 €.
- Rozalem Aranha, Mateus. Evaluation of cortical microinfarcts in individuals with Down syndrome. AARFD-21-852492. Alzheimer's Association. Duration: 2022-2025. 147.627,00 €.
- Rodríguez Baz, Iñigo. Contratos Rio Hortega 2022. CM22/00052. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2024. 65.000,00 €.
- Sala Matavera, Isabel. Estudio sobre las características del proceso de cese de la conducción en personas mayores con y sin deterioro cognitivo. INN00003. IIBSP-CON-2022-11. Fundación MAPFRE. Duration: 2022-2023. 19.123,70 €.
- Sánchez Aced, Erika. Contratos i-PFIS 2022. IFI22/00015. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2026. 89.900,00 €.
- Santos Santos, Miguel Angel. Contratos Juan Rodés 2018. JR18/00018. Instituto de Salud Carlos III (ISCIII). Duration: 2019-2023. 180.000,00 €.
- Santos Santos, Miguel Angel. Afasia primaria progresiva: Caracterización multimodal de los síntomas, fisiopatología y progresión. PI19/00882. Instituto de Salud Carlos III (ISCIII). Duration: 2020-2024. 111.320,00 €.
- Santos Santos, Miguel Angel. Rehabilitating Communication in bilingual Speakers with Language-Prominent Dementia. UT AUSTIN GRANT. Texas Global. Duration: 2021-2023. 18.811,00 €.
- Santos Santos, Miguel Angel. Molecular bases of bilingualism's protective effect vs cognitive decline. AACSF-22-972945. Alzheimer's Association. Duration: 2023-2025. 164.789,51 €.
- Santos Santos, Miguel Angel. Bilingual Factors Associated with Cognitive Reserve and Linguistic Resilience in Hispanics with Primary Progressive Aphasia. NIH - UTexas 1R01AG080470-01. National Institute on Aging (NIA) at the National Institute of Health (NIH). Duration: 2023-2027. 1.063.462,00 €.
- Sirisi Dolcet, Sónia. Ayudas para contratos Juan de la Cierva - Incorporación 2019. IJC2019-038962-I. Ministerio de Ciencia e Innovación (MICINN). Duration: 2021-2024. 93.000,00 €.
- Zhu, Nuole. Contractes Rio Hortega 2021. CM21/00113. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2023. 65.000,00 €.
- Valle Tamayo, Natalia. Contratos PFIS 2022. FI22/00077. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2026. 119.567,00 €.

GRANTS AWARDED

- Dols Icardo, Oriol. Identificación de ARN pequeños en suero como biomarcadores subrogados de los niveles de pTDP43 en el sistema nervioso central. FUNDELA 2023. Fundela Fundación Española Investigación Esclerosis Lateral (FUNDELA). Duration: 2023-2025. 50.000,00 €.
- Dols Icardo, Oriol. PMP-DEGESCO: Validation of a precision medicine tool based on online cognitive evaluation, genetic risk stratification and bloodbased biomarkers for the identification of preclinical Alzheimer's Disease. PMP22/00022. Instituto de Salud Carlos III (ISCIII). Duration: 2023-2025. 290.400,00 €.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- Fortea Ormaechea, Juan. Sleep and Temperature Disturbance as risk factors for Alzheimer's Disease in Down Syndrome: a Longitudinal Study. NIH NY Fortea 1RF1AG080769-01. National Institute on Aging (NIA) at the National Institute of Health (NIH). Duration: 2023-2028. 1.829.573,72 €.
- Fortea Ormaechea, Juan. DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's Disease. NIH FORTEA Washington 1R01AG081394-01. National Institute On Aging/NIH/DHHS. Duration: 2023-2028. 751.864,51 €.

DOCTORAL THESES DEFENDED

- Rozalem Aranha, Mateus. Cortical Microinfarcts evaluation in patients with Down syndrome. Universitat Autònoma de Barcelona; Universidade de Sao Paulo. 7/11/2023. Supervisors: Fortea Ormaechea, Juan; da Costa Leite, Cláudia; Martins Coutinho, Artur; Lleó Bisa, Alberto.
- Videla Toro, Laura. Neuropsychological and fluid biomarker changes in the Alzheimer's disease continuum in adults with Down syndrome. Universitat Autònoma de Barcelona. 25/01/2023. Supervisors: Fortea Ormaechea, Juan; Lleó Bisa, Alberto. <http://hdl.handle.net/10803/688774>.

SCIENTIFIC PRODUCTION

- Villarejo A, García E, Piñol G, del Olmo A, Viñuela F, Boada M, Franco E, de la Peña AI, Riverol M, Puig A, Abizanda P, Arroyo R, Baquero M, Feria I, Balasa M, Berbel A, Rodríguez E, Vieira A, García G, Rodrigo S, Lleó A, Maurino J. Medical help-seeking intentions among patients with early Alzheimer's disease. *Frontiers in Psychiatry*. 2023; 14:1290002. DOI:10.3389/fpsy.2023.1290002. PMID:38173708. IF:4,700 (Q2/3D). Document type: Article.
- Acha B, Corroza J, de Gordo JSR, Cabello C, Robles M, Mendez I, Macías M, Zueco S, Roland M, Urdániz A, Jericó I, Erro ME, Alcolea D, Lleó A, Blanco I, Mendioroz M, iBEAS GRP. Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease. *NEUROLOGY*. 2023; 101(23). DOI:10.1212/WNL.0000000000207865. PMID:37827850. IF:9,900 (Q1/1D). Document type: Article.
- Guillén N, Contador J, Buongiorno M, Alvarez I, Culell N, Alcolea D, Lleó A, Fortea J, Piñol G,

Carnes A, Ispuerto ML, Vilas D, Puig A, Fernández A, Balasa M, Sánchez R, Lladó A. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. *EUROPE-AN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE*. 2023; DOI:10.1007/s00406-023-01701-y. PMID:37898567. IF:4,700 (Q1/3D). Document type: Article.

- Olazarán J, Carnero C, Fortea J, Sánchez P, García G, Vinuela F, Martínez P, Boada M. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact. *Alzheimers Research & Therapy*. 2023; 15(1):130. DOI:10.1186/s13195-023-01271-0. PMID:37537656. IF:9,000 (Q1/1D). Document type: Article.
- Fortea J, García E, García G, Canal N, Maurino J. Burnout among neurologists caring for patients with cognitive disorders in Spain. *PLoS One*. 2023; 18(5):e0286129. DOI:10.1371/journal.pone.0286129. PMID:37228146. IF:3,700 (Q2/4D). Document type: Article.
- Mansilla A, Canyelles M, Ferrer R, Arranz J, Rodríguez I, Zhu N, Rubio S, El Bounasri S, Sanchez O, Torres S, Fortea J, Lleó A, Alcolea D, Tondo M. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease. *CLINICAL CHEMISTRY AND LABORATORY MEDICINE*. 2023; 61(9). DOI:10.1515/cclm-2023-0245. PMID:37083158. IF:6,800 (Q1/2D). Document type: Article.
- Videla L, Benejam B, Carmona M, Barroeta I, Fernández S, Arranz J, Azzahchi SE, Altuna M, Padilla C, Valldeneu S, Pegueroles J, Montal V, Aranha MR, Vaqué L, Iulita MF, Alcolea D, Bejanin A, Videla S, Blesa R, Lleó A, Fortea J. Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. *Alzheimers & Dementia*. 2023; 19(9). DOI:10.1002/alz.13073. PMID:37038748. IF:14,000 (Q1/1D). Document type: Article.
- Ferrer P, Puertollano D, Querol M, Sánchez É, Valle N, Cervantes A, Nuñez R, Pegueroles J, Dols O, Iulita MF, Aldecoa I, Molina L, Sánchez R, Fortea J, Belbin O, Sirisi S, Lleó A. Amyloid precursor protein BCTF accumulates in synapses in sporadic and genetic forms of Alzheimer's disease.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2023; 49(1):e12879. DOI:10.1111/nan.12879. PMID:36702749. IF:5,000 (Q1/2D). Document type: Article.
- Álvarez R, Dols O, El Bounasri S, López L, Trujillo JC, Reyes D, Suárez X, Cortés E, Illa I, Gallardo E. Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis. *Neurology-Neuroimmunology & Neuroinflammation*. 2023; 10(2):e200085. DOI:10.1212/NXI.0000000000200085. PMID:36697230. IF:8,800 (Q1/1D). Document type: Article.
 - De Luna N, Carbayo Á, Dols O, Turon J, Reyes D, Illan I, Jericó I, Pagola I, Lleixà C, Querol L, Rubio S, Alcolea D, Fortea J, Lleó A, Cortés E, Rojas R. Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis. *Neurology-Neuroimmunology & Neuroinflammation*. 2023; 10(2):e200072. DOI:10.1212/NXI.0000000000200072. PMID:36460480. IF:8,800 (Q1/1D). Document type: Article.
 - Borrego S, Montagut N, Martín P, Vaqué L, Illán I, Balasa M, Lladó A, Casanova J, Bargalló N, Valls J, Lleó A, Bartrés D, Sánchez R. Multifocal Transcranial Direct Current Stimulation in Primary Progressive Aphasia Does Not Provide a Clinical Benefit Over Speech Therapy. *JOURNAL OF ALZHEIMERS DISEASE*. 2023; 93(3). DOI:10.3233/JAD-230069. PMID:37182884. IF:4,000 (Q2/4D). Document type: Article.
 - Fitri FI, Lage C, Mollayeva T, Santamaria H, Chan MLS, Cominetti MR, Daria T, Fallon G, Gately D, Gichu M, Gimenez S, Zuniga RG, Hadad R, Hill T, O'Kelly M, Martinez L, Modjaji P, Ngcobo N, Nowak R, Ogbuagu C, Roche M, Aguzzoli CS, Shin SY, Smith E, Yoseph SA, Zewde Y, Ayhan Y. Empathy as a crucial skill in disrupting disparities in global brain health. *Frontiers in Neurology*. 2023; 14:1189143. DOI:10.3389/fneur.2023.1189143. PMID:38162446. IF:3,400 (Q2/5D). Document type: Article.
 - Hirschberg Y, Valle N, Dols O, Engelborghs S, Buelens B, Vandenbroucke RE, Vermeiren Y, Boonen K, Mertens I. Proteomic comparison between non-purified cerebrospinal fluid and cerebrospinal fluid-derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia. *Journal of Extracellular Vesicles*. 2023; 12(12):e12383. DOI:10.1002/jev2.12383. PMID:38082559. IF:16,000 (Q1/1D). Document type: Article.
 - Goossens J, González AC, Dewit N, Lidón L, Fortea J, Alcolea D, Lleó A, Belbin O, Vanmechelen E. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum. *Alzheimers Research & Therapy*. 2023; 15(1):186. DOI:10.1186/s13195-023-01336-0. PMID:37898760. IF:9,000 (Q1/1D). Document type: Article.
 - Neumann A, Ohlei O, Küçükali F, Bos IJ, Timsina J, Vos S, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenbergh R, Scheltens P, Teunissen CE, Engelborghs S, Frisoni GB, Blin O, Richardson JC, Bordet R, Lleó A, Alcolea D, Popp J, Marsh TW, Grijala P, Clark C, Peyratout G, Martinez P, Tainta M, Dobson RJB, Legido C, Van C, Tanzi RE, Ten M, Lill CM, Barkhof F, Cruchaga C, Lovestone S, Streffer J, Zetterberg H, Visser PJ, Sleegers K, Bertram L, EMIF &. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning. *Genome Medicine*. 2023; 15(1):79. DOI:10.1186/s13073-023-01233-z. PMID:37794492. IF:12,300 (Q1/1D). Document type: Article.
 - Lorca DL, Gajardo A, Mandelli ML, Illán I, Ezzes Z, Wauters LD, Battistella G, Bogley R, Ratnasiri B, Licata AE, Battista P, García AM, Tee BL, Lukic S, Boxer AL, Rosen HJ, Seeley WW, Grinberg LT, Spina S, Miller BL, Miller ZA, Henry ML, Dronkers NF, Gorno ML. Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum. *BRAIN*. 2023; DOI:10.1093/brain/awad327. PMID:37769652. IF:14,500 (Q1/1D). Document type: Article.
 - Gasca C, Trompeta C, López M, Rodríguez R, Clarimon J, Dols O, El Bounasri S, Guida P, Mata D, Hernández F, Marras C, García L, Plaza de Las Heras I, Obeso I, Vela L, Fernández B. Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease. *JOURNAL OF NEUROIMAGING*. 2023; 33(6). DOI:10.1111/jon.13156. PMID:37726927. IF:2,400 (Q3/6D). Document type: Article.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok YS, Lleó A, Alcolea D, van M, Engelborghs S, van JL, Arezoumandan S, Chen A, Irwin DJ, van der Flier WM, Lemstra AW, Teunissen CE. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease. *Nature Communications*. 2023; 14(1):5635. DOI:10.1038/s41467-023-41122-y. PMID:37704597. IF:16,600 (Q1/1D). Document type: Article.
- Mulet L, Solé C, Cabello M, Abellaneda K, Perellón R, Cattaneo G, Solana J, Alvarez V, Bargalló N, Tormos JM, Pascual A, Bartrés D, Vaqué L. Brain connectivity correlates of cognitive dispersion in a healthy middle-aged population: influence of subjective cognitive complaints. *JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES*. 2023; 78(11). DOI:10.1093/geronb/gbad114. PMID:37587033. IF:6,200 (Q1/2D). Document type: Article.
- Dou J, Bakulski K, Guo K, Hur J, Zhao L, Saez S, Stark A, Chia R, García A, Rojas R, Vázquez JF, Fernández R, Andrés S, Gómez P, Periñán MT, Mir P, Pérez J, Cardona F, Menéndez M, Riancho J, Borrego D, Galán L, Infante J, Pastor P, Paradas C, Dols O, Traynor BJ, Feldman EL, Goutman SA, Spanish C. Cumulative Genetic Score and C9orf72 Repeat Status Independently Contribute to Amyotrophic Lateral Sclerosis Risk in 2 Case-Control Studies. *Neurology-Genetics*. 2023; 9(4):e200079. DOI:10.1212/NXG.000000000200079. PMID:37293291. IF:3,100 (Q2/5D). Document type: Article.
- Gagliardi G, Rodríguez E, Montal V, Sepulcre J, Diez I, Lois C, Hanseeuw B, Schultz AP, Properzi MJ, Papp KV, Marshall GA, Fortea J, Johnson KA, Sperling RA, Vannini P. Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid. *Communications Medicine*. 2023; 3(1):106. DOI:10.1038/s43856-023-00324-7. PMID:37528163. Document type: Article.
- Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lleó A. Blood Biomarkers in Neurodegenerative Diseases Implications for the Clinical Neurologist. *NEUROLOGY*. 2023; 101(4)DOI:10.1212/WNL.000000000207193. PMID:36878698. IF:9,900 (Q1/1D). Document type: Review.
- Hok YS, Bolsewig K, Ruiters DN, Lleó A, Alcolea D, Lemstra AW, van der Flier WM, Teunissen CE, del Campo M. Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2023; 15(3):e12456. DOI:10.1002/dad2.12456. PMID:37502019. Document type: Article.
- Franzen S, Nuytemans K, Bourdage R, Caramelli P, Ellajosyula R, Finger E, Illan I, Loi SM, Morhardt D, Pijnenburg Y, Rascovsky K, Williams MM, Yokoyama JS, Alladi S, Ayhan Y, Broce I, Castro S, Coleman K, de Souza LC, Dacks PA, de Boer SCM, de Leon J, Dodge S, Grasso S, Gupta V, Gupta V, Ghoshal N, Kamath V, Kumfor F, Mattias JA, Narme P, Nielsen TR, Okhuevbie D, Pina SD, García RR, Scarioni M, Slachevsky A, Suarez A, Tee BL, Tsoy E, Ulugut H, Babulal GM, Onyike CU, ISTAART FTD, ISTAART Diversity Disparities P. zZ Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities-focused research. *Alzheimers & Dementia*. 2023. DOI:10.1002/alz.13129. PMID:37270665. IF:14,000 (Q1/1D). Document type: Article.
- Gonzalez MC, Tovar DA, Alves G, Dalen I, Williams CH, Camacho M, Forsgren L, Backstrom D, Lawson RA, Macleod AD, Counsell CE, Paquet C, DeLena C, D'Antonio F, Pilotto A, Pado-vani A, Blanc F, Falup C, Lewis SJG, Rejdak K, Papuc E, Hort J, Nedelska Z, O'Brien J, Bonanni L, Marquie M, Boada M, Pytel V, Abdelnour C, Alcolea D, Beyer K, Tysnes OB, Aarsland D, Maple J. Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia. *Movement Disorders Clinical Practice*. 2023; 10(6). DOI:10.1002/mdc3.13752. PMID:37332651. IF:4,000 (Q2/4D). Document type: Article.
- Aranha MR, Coutinho AM, Carneiro CD, Pastorello BF, Studart A, Guariglia CC, Tsunemi MH, Moreira E, Ianof JN, Anghinah R, Nitrini R, Cerri GG, Fortea J, Buchpiguel CA, Leite CC. Brain glucose metabolism and gray matter volume in retired professional soccer players: a cross-sectional [F-18]FDG-PET/MRI study. *ARQUIVOS DE NEURO-PSIQUIATRIA*. 2023; 81(05). DOI:10.1055/s-0043-1768666. PMID:37257463. IF:1,400 (Q4/9D). Document type: Article.



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

- Aranha MR, Iulita MF, Montal V, Pegueroles J, Bejanin A, Vaqué L, Grothe MJ, Carmona M, Videla L, Benejam B, Arranz J, Padilla C, Valldeneu S, Barroeta I, Altuna M, Fernández S, Ribas L, Valle N, Alcolea D, González S, Bargalló N, Zetterberg H, Blennow K, Blesa R, Wis-niewski T, Busciglio J, Cuello AC, Lleó A, Fortea J. Basal forebrain atrophy along the Al-zheimer's disease continuum in adults with Down syndrome. *Alzheimers & Dementia*. 2023; 19(11). DOI:10.1002/alz.12999. PMID:37021589. IF:14,000 (Q1/1D). Document type: Article.
- Montoliu L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, Lantero J, Carmona M, Wagemann O, Balasa M, Kac PR, Barroeta I, Llado A, Brum WS, Videla L, Gonzalez F, Bene-jam B, Martinez J, Karikari TK, Nubling G, Bejanin A, Benedet AL, Blesa R, Lleo A, Blennow K, Sánchez R, Zetterberg H, Fortea J. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. *EBioMedicine*. 2023; 90:104547. DOI:10.1016/j.ebiom.2023.104547. PMID:37002988. IF:11,100 (Q1/1D). Document type: Article.
- Abellaneda K, Cattaneo G, Cabello M, Solana J, Mulet L, Vaque L, Perellon R, Sole C, Bar-gallo N, Tormos JM, Pascual A, Bartres D. Purpose in life promotes resilience to age-related brain burden in middle-aged adults. *Alzheimers Research & Therapy*. 2023; 15(1):49. DOI:10.1186/s13195-023-01198-6. PMID:36915148. IF:9,000 (Q1/1D). Document type: Article.
- Iulita MF, Bejanin A, Vilaplana E, Carmona M, Benejam B, Videla L, Barroeta I, Fernández S, Altuna M, Pegueroles J, Montal V, Valldeneu S, Gimenez S, González S, Torres S, El Bennadi SE, Padilla C, Aranha MR, Estelles T, Illán I, Belbin O, Valle N, Camacho V, Blessing E, Osorio RS, Videla S, Lehmann S, Holland AJ, Zetterberg H, Blennow K, Alcolea D, Clarimón J, Zaman SH, Blesa R, Lleó A, Fortea J. Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome. *Brain Communications*. 2023; 5(2):fcad074. DOI:10.1093/braincomms/fcad074. PMID:37056479. Document type: Article.
- Shi L, Xu J, Green R, Wretlind A, Homann J, Buckley NJ, Tijms BM, Vos SJB, Lill CM, Kate MT, Engelborghs S, Sleegers K, Frisoni GB, Wallin A, Lleó A, Popp J, Martinez P, Streffer J, Barkhof F, Zetterberg H, Visser PJ, Lovestone S, Bertram L, Nevado AJ, Proitsi P, Legido C. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. *Alzheimers & Dementia*. 2023; 19(8). DOI:10.1002/alz.12961. PMID:36790009. IF:14,000 (Q1/1D). Document type: Article.
- Fortea J, Quiroz YT, Ryan NS. Lessons from Down syndrome and autosomal dominant Al-zheimer's disease. *LANCET NEUROLOGY*. 2023; 22(1). DOI:10.1016/S1474-4422(22)00437-9. PMID:36517171. IF:48,000 (Q1/1D). Document type: Editorial Material.
- Friedberg A, Pasquini L, Diggs R, Glaubitz EA, López L, Illán I, Iaccarino L, La Joie R, Munda N, Knudtson M, Neylan K, Brown J, Allen IE, Rankin KP, Bonham LW, Yokoyama JS, Ramos EM, Geschwind DH, Spina S, Grinberg LT, Miller ZA, Kramer JH, Rosen H, Gorno ML, Rabinovici G, Sealey WW, Miller BL. Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia. *JAMA Neurology*. 2023; 80(4). DOI:10.1001/jamaneurol.2023.0001. PMID:36848111. IF:29,000 (Q1/1D). Document type: Article.
- Hamlett ED, Flores L, Handen B, Potier M-C, Granholm A-C, Sherman S, Puig V et al. Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society. ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND:KARGER. 2023. p.p. 89-100. Document type: Conference Paper.
- Colom M, Davies C, Sirisi S, Lee J-E, Simzer EM, Tzioras M, Querol M, Sánchez É, Chang YY, Holt K, McGeachan RI, Rose J, Tulloch J, Wilkins L, Smith C, Andrian T, Belbin O, Pujals S, Horrocks MH, Lleó A, Spires TL. Synaptic oligomeric tau in Alzheimer's disease — A potential culprit in the spread of tau pathology through the brain. *NEURON*. 2023; 111(14):2170-2183.e6. DOI:10.1016/j.neuron.2023.04.020. PMID:37192625. IF:16,200 (Q1/1D). Document type: Article.
- Grasso SM, Rodríguez C, Colomer NM, Kiderle SKM, Sáanchez R, Santos M. Bilingual Primary



5.1.3 Neurological Diseases, Neuroscience & Mental Health Area

Progressive Aphasia: A Scoping Review of Assessment and Treatment Practices. JOURNAL OF ALZHEIMERS DISEASE. 2023; 96(4). DOI:10.3233/JAD-230673. PMID:37980666. IF:4,000 (Q2/4D). Document type: Review.

- McGlinchey E, Iulita MF, Fortea J. Compounded inequality: racial disparity and Down syndrome. Lancet Public Health. 2023; 8(11). DOI:10.1016/S2468-2667(23)00213-X. IF:50,000 (Q1/1D). Document type: Letter.
- Giménez S, Tapia IE, Fortea J, Levedowski D, Osorio R, Hendrix J, Hillerstrom H. Caregiver knowledge of obstructive sleep apnoea in Down syndrome. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH. 2023; 67(1). DOI:10.1111/jir.12990. PMID:36416001. IF:3,600 (Q1/1D). Document type: Article.
- Fortea J, García E, Terrance A, Galvez B, Diez V, Rebollo P, Maurino J, García G. Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer's Disease. JOURNAL OF ALZHEIMERS DISEASE. 2023; 93(1). DOI:10.3233/JAD-221160. PMID:36970902. IF:4,000 (Q2/4D). Document type: Article.
- Trifunov S, Natera D, Carrera L, Codina A, Expósito J, Ortez C, Medina J, Alcalá ST, Bernal S, Alias L, Badosa C, Balsells S, Alcolea D, Nascimento A, Jimenez C. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen. Journal Of Neuromuscular Diseases. 2023; 10(4). DOI:10.3233/JND-230012. PMID:37038823. IF:3,300 (Q2/5D). Document type: Article.
- Rafii MS, Fortea J. Down Syndrome in a New Era for Alzheimer Disease. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2023; 330(22). DOI:10.1001/jama.2023.22924. PMID:37991807. IF:120,700 (Q1/1D). Document type: Article.